News
Merck to Acquire SmartCells, Inc
Merck & Co., Inc., and SmartCells, Inc., announced that they have entered into a definitive agreement under which Merck will acquire SmartCells, a private company developing a glucose responsive insulin formulation for the treatment of diabetes mellitus. ...
News
Cold Chain Smart Solutions Conference
While cold chain management is becoming an evermore important part of a pharmaceutical firm’s business capability, it is also big business from the logistics point of view. Pharma Supply Chain is a complex interplay of product,...
News
Ranbaxy Launches Donepezil 5MG and 10MG Tablets
Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received final approval from the U.S. FDA to manufacture and market Donepezil Hydrochloride Tablets 5 mg and 10 mg with 180 day market...
News
Quintiles and London Genetics Alliance T0 Enchance Drug Discovery and Development
Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance...
News
Vertex Completes New Drug Application for Telaprevir for Hepatitis C
Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the FDA seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C. The NDA submission is supported by results from...
News
Sun Pharma announces FDA tentative approval for generic Cymbalta
Sun Pharmaceutical Industries Ltd. announced US FDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride...
News
Lilly and Acrux Receive FDA Approval for Axiron Topical Solution CIII
Eli Lilly and Company and Acrux announced that the U.S. FDA has approved Axiron topical solution CIII for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone. Safety and efficacy of Axiron in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
